广州白云山和记黄埔中药有限公司

What 广州白云山和记黄埔中药有限公司 does

广州白云山和记黄埔中药有限公司 (Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd.) is a Chinese traditional medicine manufacturer formed in 2005 as a joint venture between Guangzhou Pharmaceutical Group's Baiyunshan Pharmaceutical and Hutchison Whampoa (China). The company operates from Guangzhou with a manufacturing subsidiary in Shantou, and is designated a National High-Tech Enterprise and National Innovative Enterprise. Its roots trace back to a 1956 farm operation area that became the Guangzhou Baiyunshan Chinese Medicine Factory in 1988 before its 2005 JV formation.

The company's core business is R&D and manufacture of modern Chinese patent medicines spanning five therapeutic areas: respiratory (板蓝根颗粒 / Banlangen Granules, 复方板蓝根颗粒, 口炎清颗粒, 感冒灵颗粒), cardiovascular (复方丹参片 / Compound Danshen Tablets, 脑心清片, 三七粉), digestive (消炎利胆片, 胆康片, 健胃消食片, 护肝片), oral/nasal/throat (防芷鼻炎片, 千柏鼻炎片), and pediatric/general health categories. Its proprietary technology stack spans GAP medicinal herb cultivation, extraction/separation, advanced formulation, and a five-tier quality control system anchored in fingerprint chromatography. Core patent estates include 12 patents on Naoxinqing Tablets (China Patent Excellence Award, 21st session), 9 patents on Banlangen Granules (19th session), 8 patents on Kouyangqing Granules (15th session, National Class II TCM Protected Variety), and 7 patents on Compound Danshen Tablets. Manufacturing inputs are sourced from 10+ GAP-certified herb bases across Anhui, Guangdong, Henan, Yunnan, Heilongjiang, and Xinjiang.

The company generates revenue primarily through one-time sales of branded OTC medicines via two channels: a domestic channel consisting of 6,600 proprietary "永不过期" branded pharmacies plus medical commercial wholesalers serving hospitals and clinics, and an overseas channel leveraged through Hutchison's Watsons, PARKnSHOP, and 5,000+ European retail terminals. Strategic partnerships with national chain pharmacy leaders (Yixintang, Tongrentang, Yikang, Zhongyou, Wanning, Deshentang, Haoyisheng, Good Pharmacist, Wanhe) deepen terminal coverage. The Shennong Herbal Garden TCM Museum functions as a brand-building, cultural-education, and health-tourism platform, receiving nearly 3 million visitors. Distribution is reinforced by R&D collaborations with Academician Zhong Nanshan (respiratory/antiviral), Academician Liu Changxiao (modern TCM), and Nobel laureate Ferid Murad (cardiovascular), and the Banlangen Granules franchise is the only TCM product to receive US NIH research funding.

Name

广州白云山和记黄埔中药有限公司

Legal name

广州白云山和记黄埔中药有限公司

Website

https://813zy.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. is a joint-venture modern TCM manufacturer developing and selling branded Chinese patent medicines (respiratory, cardiovascular, digestive, oral care) through 6,600 domestic branded pharmacies, top-100 national chain partners, and Hutchison's overseas retail network serving mass-market consumers across China and 5,000+ international terminals.

Ownership category

akta.pro rank

Product category

Chinese Patent Medicine (中成药)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

akta.pro secondary industries

Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Chinese patent medicine
• Traditional Chinese medicine pharmaceuticals
• OTC medicines
• Chinese herbal preparations
• Pharmaceutical manufacturing

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. 中成药工业销售: 以复方丹参片、板蓝根颗粒、口炎清颗粒、脑心清片、三七粉等品牌中成药产品通过医药商业公司和连锁药店渠道销售，实现工业销售规模。十三五规划目标工业销售30亿元。
2. 医药商业销售: 通过医药商业渠道分销中成药和化学药品，十三五规划目标商业销售20亿元。
3. 大健康产品: 以板蓝根颗粒、口炎清颗粒、三七粉等产品为核心，延伸大健康产品线，扩大消费群体覆盖面。

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. is a national high-tech pharmaceutical manufacturer that develops, produces, and sells Chinese patent medicines (中成药) including flagship brands such as Compound Danshen Tablets (复方丹参片), Banlangen Granules (板蓝根颗粒), Kouyanqing Granules (口炎清颗粒), and Sanqi Powder (三七粉). The company sells its products through a nationwide network of chain pharmacies and medical commercial distribution channels, covering treatment areas including respiratory, cardiovascular, digestive, and oral/throat health. Its wholly-owned subsidiary Laida Pharmaceutical in Shantou produces additional Western and Chinese medicines across cardiovascular, digestive, respiratory, pediatric, gynecological, and infectious disease areas, and operates as a full contract manufacturer under the MAH (Marketing Authorization Holder) system.

Product overview

广州白云山和记黄埔中药有限公司是一家专注于现代中药研发与制造的国家级高新技术企业，由广药集团白云山制药股份有限公司与和记黄埔（中国）公司于2005年合资成立。公司产品涵盖8大治疗领域：呼吸系统类（板蓝根颗粒、复方板蓝根颗粒、口炎清颗粒、感冒灵颗粒等）、心脑血管类（复方丹参片、脑心清片、三七粉、绞股蓝总甙片、丹红化瘀口服液）、消化系统类（消炎利胆片、利胆排石片、胆康片、枫蓼肠胃康片、健胃消食片、护肝片）、口腔耳鼻喉类、内分泌类、儿科类、男科类、骨科类用药，以及子公司莱达制药产品（心脉安片、消炎利胆片、胃灵颗粒等）。核心产品包括复方丹参片（拥有7项专利，药材基地通过GAP认证）、板蓝根颗粒（拥有9项专利，第十九届中国专利优秀奖）、口炎清颗粒（国家二级中药保护品种，拥有8项专利，第十五届中国专利优秀奖）、脑心清片（独家品种，拥有12项专利，荣获2015年国家科技进步二等奖）。

Differentiator

Problem solved

Functional benefit

Brands

• 神农草堂 (Shennong Herbal Garden): TCM museum and cultural complex showcasing traditional Chinese medicine history, Lingnan medicine, and over 1,000 medicinal plant species. Recognized as a national TCM culture education base.

Products and services

• 板蓝根颗粒 (Banlangen Granules)

Quantifiable outcome

• 1999年—2013年企业规模扩大30倍，四项指标保持30%以上增长
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

16 partnerships are on record, tiered core and minor.

• 刘昌孝院士团队coreStrategic or Co-development Partner · 1 December 2021刘昌孝院士担任企业现代中药研究院院长，与白云山和黄合作开展脑心清片和口炎清颗粒的二次开发研究，2021年在创交会院士成果展区展示最新研究进展
• 广州名优中成药产学研技术创新联盟coreStrategic or Co-development Partner · 1 March 20162016年3月成立，由广州医药集团有限公司牵头，联盟秘书处依托单位为白云山和黄中药，成员包括广州白云山医药集团、广州医药研究总院、暨南大学、中国中医科学院中药研究所等22家单位，联合国内医药领域特色企业和研究机构，以市场为导向、以产品为核心，建立产学研联盟体系
• 和记黄埔（中国）公司coreStrategic or Co-development Partner · 1 May 2005广药集团白云山制药股份有限公司与和记黄埔（中国）公司于2005年5月合资成立广州白云山和记黄埔中药有限公司，合资方带来全球零售渠道资源（屈臣氏、百佳及欧洲5000+零售终端）和先进企业管理经验
• 广药集团白云山制药股份有限公司coreStrategic or Co-development Partner · 1 January 2005广药集团白云山制药股份有限公司作为中方合资主体，与和记黄埔共同成立合资公司，提供国内医药行业资源和政策支持
• 诺贝尔奖得主穆拉德（伟哥之父）coreStrategic or Co-development Partner与诺贝尔奖得主、伟哥之父穆拉德联合开发复方丹参片等产品研究，将其应用于心脑血管疾病治疗研究
• 钟南山院士coreStrategic or Co-development Partner与钟南山院士合作共建呼吸疾病国家重点实验室，由钟南山院士为带头人成立白云山和黄中药抗病毒研究中心，开展板蓝根等抗病毒药物研究
• 军事医学科学院minorStrategic or Co-development Partner与军事医学科学院联合招收博士后，开展基础药理学、心脑血管疾病和老年神经退行性疾病研究
• 中国医学科学院药用植物研究所minorStrategic or Co-development Partner与中国医科院药植所合作完成药用植物——丹参基因组框架图，推进中药现代化研究
• 暨南大学minorStrategic or Co-development Partner广州名优中成药产学研技术创新联盟成员单位，与公司开展中医药研发合作
• 中国中医科学院中药研究所minorStrategic or Co-development Partner广州名优中成药产学研技术创新联盟成员单位，参与中药研究合作
• 广州中医药大学minorStrategic or Co-development Partner与广州中医药大学共建神农学院，开展中医药人才培养和文化传播合作
• 南方医科大学minorStrategic or Co-development Partner广州名优中成药产学研技术创新联盟成员单位
• 广州医药研究总院有限公司minorStrategic or Co-development Partner广州名优中成药产学研技术创新联盟成员单位，广药集团研发总部
• 广东省中医院minorStrategic or Co-development Partner与广东省中医院共建中医药文化传播基地
• 广之旅minorStrategic or Co-development Partner与广之旅共建健康旅游基地，推进神农草堂文化旅游合作
• 苏国辉院士minorStrategic or Co-development Partner中国科学院院士、香港大学/暨南大学中枢神经再生研究院院长，出席2021年全国第六届防治老年痴呆症高峰论坛并做学术报告

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Dong-E E-Jiao (东阿阿胶): Classic TCM consumer brand with strong pharmacy channel distribution and category leadership in a single therapeutic area. Comparable for TCM brand equity and OTC pharmacy execution.
• Beijing Tongrentang (同仁堂): China's most iconic TCM brand with parallel OTC and chain-pharmacy distribution model, multi-category portfolio, and similar reliance on 中成药 preparations. Closest publicly-listed comparable for brand-equity and channel structure.
• Sunflower Pharmaceutical Group (葵花药业): OTC pharma group with strong children's TCM franchise (小儿肺热咳喘, 小儿氨酚黄那敏) and broad respiratory/gastrointestinal portfolio sold through national chains — closely comparable in pediatric TCM and OTC category strategy.
• CR Sanjiu Medical & Pharmaceutical (华润三九): Leading Chinese OTC/TCM company under China Resources with parallel cold/cough, ENT and pediatric categories and similar chain-pharmacy GTM. Strong comparable for branded TCM and OTC respiratory franchise.
• Jichuan Pharmaceutical (济川药业): TCM pharma with dominant pediatric respiratory and digestive OTC franchises (蒲地蓝消炎口服液, 健胃消食口服液). Comparable in respiratory and pediatric TCM categories and chain-pharmacy execution.
• Taiji Group (太极集团): Major Chinese TCM manufacturer with a broad respiratory, cardiovascular and digestive portfolio sold through national pharmacy chains. Directly comparable product mix and OTC channel dependence.
• Guilin Sanjin Pharmaceutical (桂林三金): Regional TCM manufacturer specializing in ENT/urological indications (西瓜霜系列, 三金片) with national OTC distribution; comparable in product breadth, channel mix and TCM category focus.
• Yunnan Baiyao Group (云南白药): China's most valuable TCM brand with comparable diversification across classic TCM formulations, OTC consumer health and modern consumer products. Reference benchmark for TCM brand monetization and category extension.
• Jiangzhong Pharmaceutical (江中药业): TCM-focused company with leading OTC brands (健胃消食片, 复方草珊瑚含片) distributed through national pharmacy chains, highly comparable in OTC positioning and TCM category exposure.

Broad incumbents

• Guangzhou Pharmaceutical Group / GPHL Baiyunshan (广药集团白云山): Parent-company group and broader pharmaceutical conglomerate of which this entity is a JV subsidiary; operates the larger publicly-listed Baiyunshan pharma with broader Western drug and TCM portfolio. Useful as the controlling-parent comparable for consolidated scale and valuation reference.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E5%B9%BF%E5%B7%9E%E7%99%BD%E4%BA%91%E5%B1%B1%E5%92%8C%E8%AE%B0%E9%BB%84%E5%9F%94%E4%B8%AD%E8%8D%AF%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 广州白云山和记黄埔中药有限公司